PASI 100 rates at the same time points were 27% and 40% among patients switched from placebo to icotrokinra. IGA 0 response rate increased from 1% at 16 weeks to 23% at 24 weeks, and PASI 100 ...

The primary end point was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response; PASI scores range from 0 to 72, with higher scores ...

It has recently been claimed that patients who achieve PASI scores less than or equal to 2 within the first 6 months of initiating biologic treatment tend to exhibit more stable psoriasis and a ...

Of the 230 patients who received continuous deucravacitinib treatment and achieved PASI 75 by week 24, 60.9% achieved PASI 90 and 82.2% achieved sPGA 0/1. Response rates were generally maintained ...

The rates of response were 53%, 61%, and 64% for the 20-mg, 30-mg, ... At 4 weeks, PASI scores climbed from baseline by nearly 40% for those on all orismilast doses, ...

Although there was no statistically significant difference between the proportion of patients who achieved a PASI-50 response on EDP2939 compared to placebo, it was notable that such numeric ...

“The study’s primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI ...

The primary objectives of this study are to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared with placebo ...

The co-primary efficacy objectives of this study are the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) and the proportion of ...

A lower PASI when therapy ends (HR, 1.03; 95% CI, 1.01-1.05). This model had good predictive and discriminative ability. The sensitivity analysis showed similar results to the primary analysis.

Meanwhile, 49.6% of patients saw a 90% or more improvement in a Psoriasis Area and Severity Index (PASI 90) score from baseline, meeting the other co-primary goal. Of those on placebo, 4.4% met ...